Health economic evaluation of a web-based intervention for depression: the EVIDENT-trial, a randomized controlled study.
Depression
Deprexis
E-mental-health
Economic issues
Health economic evaluation
Outcome studies
Randomized controlled trial
Journal
Health economics review
ISSN: 2191-1991
Titre abrégé: Health Econ Rev
Pays: Germany
ID NLM: 101583209
Informations de publication
Date de publication:
07 Jun 2019
07 Jun 2019
Historique:
received:
10
12
2018
accepted:
22
05
2019
entrez:
9
6
2019
pubmed:
9
6
2019
medline:
9
6
2019
Statut:
epublish
Résumé
Depression often remains undiagnosed or treated inadequately. Web-based interventions for depression may improve accessibility of treatment and reduce disease-related costs. This study aimed to examine the potential of the web-based cognitive behavioral intervention "deprexis" in reducing disease-related costs. Participants with mild to moderate depressive symptoms were recruited and randomized to either a 12-week web-based intervention (deprexis) in addition to care as usual (intervention group) or care as usual (control group). Outcome measures were health-related resource use, use of medication and incapacity to work as well as relating direct health care costs. Outcomes were assessed on patients' self-report at baseline, three months and six months. A total of 1013 participants were randomized. In both groups total direct health care costs decreased during the study period, but changes from baseline did not significantly differ between study groups. Numeric differences between study groups existed in outpatient treatment costs. They could be attributed to differences in changes of costs for psychotherapeutic treatment from baseline. Whereas costs for psychotherapeutic treatment decreased in the intervention group, costs increased in the control group (- 16.8% (€80) vs. + 14.7% (€60)) (t The study indicates the health economic potential of innovative e-mental-health programs. There is evidence to suggest that the use of deprexis over a period of 12 weeks leads to a decrease in outpatient treatment cost, especially in those related to different types of psychotherapeutic treatment.
Sections du résumé
BACKGROUND
BACKGROUND
Depression often remains undiagnosed or treated inadequately. Web-based interventions for depression may improve accessibility of treatment and reduce disease-related costs. This study aimed to examine the potential of the web-based cognitive behavioral intervention "deprexis" in reducing disease-related costs.
METHODS
METHODS
Participants with mild to moderate depressive symptoms were recruited and randomized to either a 12-week web-based intervention (deprexis) in addition to care as usual (intervention group) or care as usual (control group). Outcome measures were health-related resource use, use of medication and incapacity to work as well as relating direct health care costs. Outcomes were assessed on patients' self-report at baseline, three months and six months.
RESULTS
RESULTS
A total of 1013 participants were randomized. In both groups total direct health care costs decreased during the study period, but changes from baseline did not significantly differ between study groups. Numeric differences between study groups existed in outpatient treatment costs. They could be attributed to differences in changes of costs for psychotherapeutic treatment from baseline. Whereas costs for psychotherapeutic treatment decreased in the intervention group, costs increased in the control group (- 16.8% (€80) vs. + 14.7% (€60)) (t
CONCLUSION
CONCLUSIONS
The study indicates the health economic potential of innovative e-mental-health programs. There is evidence to suggest that the use of deprexis over a period of 12 weeks leads to a decrease in outpatient treatment cost, especially in those related to different types of psychotherapeutic treatment.
Identifiants
pubmed: 31175475
doi: 10.1186/s13561-019-0233-y
pii: 10.1186/s13561-019-0233-y
pmc: PMC6734272
doi:
Types de publication
Journal Article
Langues
eng
Pagination
16Subventions
Organisme : Bundesministerium für Gesundheit
ID : II A 5-2512 FSB 052
Références
J Clin Epidemiol. 2000 Jul;53(7):688-95
pubmed: 10941945
Epidemiology. 2001 Jul;12(4):461-6
pubmed: 11416783
Psychiatr Prax. 2004 Apr;31(3):147-56
pubmed: 15042478
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2004 Aug;47(8):736-44
pubmed: 15340716
Bull World Health Organ. 2004 Nov;82(11):858-66
pubmed: 15640922
Br J Psychiatry. 2005 Apr;186:297-301
pubmed: 15802685
Psychiatr Prax. 2005 Apr;32(3):113-21
pubmed: 15818527
Int J Technol Assess Health Care. 2005 Summer;21(3):298-304
pubmed: 16110708
Nervenarzt. 2007 Nov;78 Suppl 3:585-94; quiz 595
pubmed: 17934708
J Med Internet Res. 2009 May 11;11(2):e15
pubmed: 19632969
Health Educ Res. 2010 Aug;25(4):585-95
pubmed: 19897515
Br J Psychiatry. 2010 Apr;196(4):310-8
pubmed: 20357309
BMC Fam Pract. 2011 Jun 18;12:51
pubmed: 21682916
PLoS One. 2011;6(6):e21274
pubmed: 21712998
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2013 May;56(5-6):733-9
pubmed: 23703492
BMC Health Serv Res. 2013 Jun 15;13:217
pubmed: 23768141
Psychol Med. 2014 Mar;44(4):741-52
pubmed: 23795621
BMC Psychiatry. 2013 Sep 28;13:239
pubmed: 24074299
Gesundheitswesen. 2015 Jan;77(1):46-52
pubmed: 24806594
Gesundheitswesen. 2015 Jan;77(1):53-61
pubmed: 25025287
BMC Med Res Methodol. 2014 Nov 19;14:118
pubmed: 25407057
Medicine (Baltimore). 2016 Mar;95(10):e2759
pubmed: 26962773
Psychother Psychosom. 2016;85(4):218-28
pubmed: 27230863
JAMA Psychiatry. 2017 Apr 1;74(4):351-359
pubmed: 28241179
Psychiatry Res. 2017 Oct;256:371-377
pubmed: 28686935
BMJ Open. 2017 Jul 13;7(7):e015391
pubmed: 28710212
J Affect Disord. 2018 Jan 1;225:733-755
pubmed: 28922737
Internet Interv. 2017 Jun 02;9:46-50
pubmed: 30135836